Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial
Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3116-3127
DOI: 10.1200/jco-25-03009 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Shaobo Mo und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colorectal Neoplasms, DNA Methylation, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
PURPOSE We hypothesized that a dynamic surveillance strategy guided by circulating tumor DNA (ctDNA) methylation would increase the rate of curative-intent therapy for recurrence in patients with nonmetastatic colorectal cancer (CRC) after curative resection. METHODS The FIND trial (ClinicalTrials.gov identifier: NCT05904665 ) is a prospective, multicenter, randomized, phase III study. Patients with nonmetastatic CRC were randomly assigned to ctDNA-guided surveillance or standard computed tomography (CT)–based monitoring. In the ctDNA-guided group, a positive ctDNA result triggered immediate CT imaging; if negative, bimonthly CT continued alongside quarterly ctDNA testing. After two consecutive ctDNA-negative results, imaging reverted to standard frequency. The primary end point was the proportion of patients with recurrence receiving curative-intent metastasis-directed therapy. RESULTS Among 584 eligible patients (289 ctDNA-guided, 295 control) in the modified intention-to-treat population, with a median follow-up of 23.3 months, recurrence rates were similar (18.0% v 18.6%, P = .919). The ctDNA-guided group had a significantly higher rate of curative-intent treatment (48.1% v 23.6%, relative risk 2.03, P = .008). The median time to clinical recurrence was significantly shorter in the ctDNA-guided group than in the control group (9.5 v 13.4 months; P < .001), representing a lead time of 3.9 months. Among recurrences confined to the liver and/or lungs, the ctDNA-guided group showed higher curative resection rates (42.3% v 18.2%, P = .002). These patients had more favorable hepatic metastatic features: fewer lesions (≤3: 75.0% v 28.6%, P = .005), smaller tumor size (≤3 cm: 90.0% v 57.1%, P = .033), and more unilobar disease (80.0% v 28.6%, P = .002). CONCLUSION ctDNA methylation-guided dynamic surveillance improves the rate of curative-intent therapy for recurrence in patients with initially nonmetastatic CRC through earlier detection of resectable metastases, pending validation of long-term survival benefit in future analyses with mature data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Pharmacy, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
- Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Maoguang Ma, Yaqi Li, Changhua Zhuo, Zhuo Lu, Shengnan Jin, Junjie Peng
Zitieren
APA
Mo, S., Zhou, C., Ma, M., Luo, W., Li, Y., Lu, P., Tang, P., Li, Y., Ma, X., Hu, X., Cheng, C., Yang, J., Zhuo, C., Jian, J., Yu, C., Ding, J., Xiong, C., Jiang, F., Mu, R., …, & Peng, J. (2026). Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial. Journal of Clinical Oncology, 44(32), 3116-3127. https://doi.org/10.1200/jco-25-03009
Vancouver
Mo S, Zhou C, Ma M, Luo W, Li Y, Lu P, et al. Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial. Journal of Clinical Oncology. 2026;44(32):3116-3127. doi:10.1200/jco-25-03009
BibTeX
@article{Mo2026,
author = {Mo, Shaobo and Zhou, Chaoqiang and Ma, Maoguang and Luo, Wenqin and Li, Yaqun and Lu, Ping and Tang, Peiyuan and Li, Yaqi and Ma, Xiaoji and Hu, Xiang and Cheng, Chunliang and Yang, Jiajun and Zhuo, Changhua and Jian, Jinliang and Yu, Cheng and Ding, Jinhuo and Xiong, Chaoxia and Jiang, Fei and Mu, Rongrong and Lu, Zhuo and Yu, Jiayi and Jin, Shengnan and Luan, Ju and Li, Xinxiang and Cai, Sanjun and Zou, Hai and Li, Yiwei and Li, Qingguo and Liu, Fangqi and Ding, Chunming and Peng, Junjie},
title = {Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {32},
pages = {3116--3127},
doi = {10.1200/jco-25-03009}
}
EUVIMED